GGrantIndex
Sort

1,049,261 grants matching t cell

PROGRAMMING SEED CELLS TO GROW AND DIFFERENTIATE INTO DEFINED PATTERNS

$2,409,578
Massachusetts Institute Of Technology · · FY2017 · Department of the Army

The CSBC Research Center for Cancer Systems Immunology at MSKCC

$2,409,446
Christina S Leslie · Sloan-Kettering Inst Can Research · U54 · FY2018 · CA

Multidisciplinary Approaches to HDL Structure, Assembly and Function

$2,409,435
Jere P Segrest · Vanderbilt University Medical Center · P01 · FY2020 · HL

Scientific innovation for personalized severe asthma management

$2,409,373
Benjamin M Gaston · Indiana University Indianapolis · P01 · FY2022 · HL

Pathophysiologic Consequences of Survival Signaling in Neuroblastoma

$2,409,315
Carol Thiele-Galetto · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA

Biomarker Rich Clinical Trial of an Innovative Antibody Antagonist of TNFR2 in Non-Hodgkin Lymphoma Featuring Cutaneous T Cell Lymphoma (CTCL).

$2,409,283
David G Brooks · Boston Immune Technologies And Therapeutics, Inc. · R44 · FY2025 · CA

GENETIC ANALYSIS OF MOUSE CHROMOSOME 11

$2,409,277
Baylor College Of Medicine · P01 · FY2001 · CA

Experimental-data-based in-silico data generation platform to improve the accuracy and reliability of single-cell and spatial omics data analysis

$2,409,233
Jingyi Jessica Li · Fred Hutchinson Cancer Center · R01 · FY2025 · HG

Life Course Cancer Epidemiology Cohort in Women

$2,409,183
Walter C. Willett · Harvard School Of Public Health · U01 · FY2021 · CA

Genetic Basis Of Cortical Malfunction In Schizophrenia

$2,409,110
Karen Faith Berman · National Institute Of Mental Health · ZIA · FY2012 · MH

Development of Novel Therapeutic Strategies in Human Leukemias

$2,408,966
James D Griffin · Dana-Farber Cancer Inst · P01 · FY2010 · CA

Retinal aging and inherited neurodegenerative diseases

$2,408,833
Anand Swaroop · National Eye Institute · ZIA · FY2013 · EY

Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.

$2,408,617
Michael G Agadjanyan · Institute For Molecular Medicine · R01 · FY2023 · AG

Tumor microenvironment in CLL and MCL: pathogenesis, targets, and therapy

$2,408,401
Adrian U Wiestner · National Heart, Lung, And Blood Institute · ZIA · FY2020 · HL

Immunopathogenesis of Fungal Infections

$2,408,398
Michail Lionakis · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI

Physics of collective cellular migration in lung health and disease

$2,408,374
Jeffrey J Fredberg · Harvard School Of Public Health · P01 · FY2017 · HL

Harnessing the power of experimental genetic crosses and systems genetics to probe drug resistance in malaria

$2,408,349
Michael T Ferdig · University Of Notre Dame · P01 · FY2017 · AI

Scientific innovation for personalized severe asthma management

$2,408,164
Benjamin M Gaston · Indiana University Indianapolis · P01 · FY2025 · HL

Immunological responses to pan-CoV vaccines

$2,408,043
Yoshihiro Kawaoka · University Of Wisconsin-Madison · P01 · FY2021 · AI

STEM CELLS AND CARDIOVASCULAR REPAIR

$2,407,992
Charles E Murry · University Of Washington · P01 · FY2013 · HL

Multi-component HIV Vaccines Using Engineered Envelopes

$2,407,540
Novartis Vaccines And Diagnostics, Inc. · P01 · FY2004 · AI

High-Throughput Nanoscale Approaches to Studying and Inhibiting Amyloid Toxicity

$2,407,500
Timothy Lu · Massachusetts Institute Of Technology · DP2 · FY2011 · OD

Accelerating drug development and repurposing using systematic genetic interactio

$2,407,500
Michael C Bassik · Stanford University · DP2 · FY2014 · HD

Genetic Analysis of Resistance to Viral Infection

$2,407,377
Bruce A Beutler · Scripps Research Institute, The · P01 · FY2007 · AI

NCIC Clinical Trials Group - Canadian Collaborating Clinical Trials Network

$2,407,344
Janet Ellen Dancey · Queen'S University At Kingston · U10 · FY2018 · CA